How we diagnose the antiphospholipid syndrome (original) (raw)

Abstract

The antiphospholipid syndrome (APS) is an acquired thrombophilia, characterized by the occurrence of venous and arterial events. This article examines the laboratory and key clinical aspects of APS. Particular focus is given to anti–beta 2-glycoprotein I (β2GPI) antibodies in view of their recent inclusion in the APS classification criteria. The clinical utility of using the β2GPI enzyme-linked immunosorbent assay, in conjunction with the established lupus anticoagulant assays and cardiolipin enzyme-linked immunosorbent assay, for diagnosing and risk stratifying patients suspected of having APS is discussed. The relative importance of the various assays in diagnosing obstetric APS (early and late gestation miscarriages) is explored. The implications of recent epidemiologic findings for possibly understanding the underlying pathophysiologic mechanisms of obstetric APS are highlighted. Insights into which patients with obstetric APS may be at most risk of thrombotic complications are ...

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (108)

  1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classifica- tion criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
  2. Harris EN, Gharavi AE, Boey ML, et al. Anticar- diolipin antibodies: detection by radioimmunoas- say and association with thrombosis in systemic lupus erythematosus. Lancet. 1983;2:1211-1214.
  3. Wilson WA, Gharavi AE, Koike T, et al. Inter- national consensus statement on preliminary classification criteria for definite antiphos- pholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42:1309- 1311.
  4. McNeil HP, Chesterman CN, Krilis SA. Anticardio- lipin antibodies and lupus anticoagulants com- prise separate antibody subgroups with different phospholipid binding characteristics. Br J Haema- tol. 1989;73:506-513.
  5. Galli M, Comfurius P, Maassen C, et al. Anticar- diolipin antibodies (ACA) directed not to cardio- lipin but to a plasma protein cofactor. Lancet. 1990;335:1544-1547.
  6. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet. 1990; 336:177-178.
  7. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid- binding inhibitor of coagulation: beta 2-glycopro- tein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990;87:4120-4124.
  8. Arvieux J, Roussel B, Jacob MC, Colomb MG. Measurement of anti-phospholipid antibodies by ELISA using beta 2-glycoprotein I as an antigen. J Immunol Methods. 1991;143:223-229.
  9. Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med. 1994;179:457-462.
  10. Roubey RA, Eisenberg RA, Harper MF, Winfield JB. "Anticardiolipin" autoantibodies recognize beta 2-glycoprotein I in the absence of phospho- lipid: importance of Ag density and bivalent bind- ing. J Immunol. 1995;154:954-960.
  11. Sheng Y, Kandiah DA, Krilis SA. Anti-beta 2-gly- coprotein I autoantibodies from patients with the "antiphospholipid" syndrome bind to beta 2-glyco- protein I with low affinity: dimerization of beta 2-glycoprotein I induces a significant increase in anti-beta 2-glycoprotein I antibody affinity. J Im- munol. 1998;161:2038-2043.
  12. de Laat B, Derksen RH, van Lummel M, Pennings MT, de Groot PG. Pathogenic anti- beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conforma- tional change. Blood. 2006;107:1916-1924.
  13. Hunt JE, McNeil HP, Morgan GJ, Crameri RM, Krilis SA. A phospholipid-beta2-glycoprotein I complex is an antigen for anticardiolipin antibod- ies occurring in autoimmune disease but not with infection. Lupus. 1992;1:75-81.
  14. Santiago M, Martinelli R, Ko A, et al. Anti-beta2 glycoprotein I and anticardiolipin antibodies in leptospirosis, syphilis and Kala-azar. Clin Exp Rheumatol. 2001;19:425-430.
  15. Arvieux J, Renaudineau Y, Mane I, Perraut R, Krilis SA, Youinou P. Distinguishing features of anti-beta2 glycoprotein I antibodies between patients with leprosy and the antiphospholipid syndrome. Thromb Haemost. 2002;87: 599-605.
  16. Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recog- nize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A. 1998;95:15542-15546.
  17. Reddel SW, Wang YX, Sheng YH, Krilis SA. Epitope studies with anti-beta 2-glycoprotein I antibodies from autoantibody and immunized sources. J Autoimmun. 2000;15:91-96.
  18. Iverson GM, Reddel S, Victoria EJ, et al. Use of single point mutations in domain I of beta 2-glyco- protein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol. 2002;169:7097-7103.
  19. de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40- Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood. 2005;105:1540-1545.
  20. Ioannou Y, Pericleous C, Giles I, Latchman DS, Isenberg DA, Rahman A. Binding of antiphospho- lipid antibodies to discontinuous epitopes on do- main I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum. 2007;56:280-290.
  21. Guerin J, Casey E, Feighery C, Jackson J. Anti- beta 2-glycoprotein I antibody isotype and IgG subclass in antiphospholipid syndrome patients. Autoimmunity. 1999;31:109-116.
  22. de Larranaga GF, Forastiero RR, Martinuzzo ME, et al. High prevalence of antiphospholipid anti- bodies in leprosy: evaluation of antigen reactivity. Lupus. 2000;9:594-600.
  23. Galli M, Comfurius P, Barbui T, Zwaal RF, Bevers EM. Anticoagulant activity of beta 2-glycoprotein I is potentiated by a distinct subgroup of anticardio- lipin antibodies. Thromb Haemost. 1992;68:297- 300.
  24. Roubey RA, Pratt CW, Buyon JP, Winfield JB. Lupus anticoagulant activity of autoimmune an- tiphospholipid antibodies is dependent upon beta 2-glycoprotein I. J Clin Invest. 1992;90:1100- 1104.
  25. Oosting JD, Derksen RH, Entjes HT, Bouma BN, de Groot PG. Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein I. Thromb Haemost. 1992; 67:499-502.
  26. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgG's (LA) are not di- rected to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Hae- most. 1991;66:629-632.
  27. Oosting JD, Derksen RHWM, Bobbink IW, Hackeng TM, Bouma B, de Groot PG. Antiphos- pholipid antibodies directed against a combina- tion of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood. 1993;81:2618-25.
  28. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for throm- bosis than anticardiolipin antibodies in the an- tiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827-1832.
  29. Brandt JT, Barna LK, Triplett DA. Laboratory iden- tification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Sub- committee on Lupus Anticoagulants/Antiphos- pholipid Antibodies of the ISTH. Thromb Hae- most. 1995;74:1597-1603.
  30. Jennings I, Kitchen S, Woods TA, Preston FE, Greaves M. Potentially clinically important inac- curacies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation. Thromb Hae- most. 1997;77:934-937.
  31. Favaloro EJ, Bonar R, Sioufi J, et al. Multilabora- tory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology. Se- min Thromb Hemost. 2005;31:49-58.
  32. Pengo V, Biasiolo A, Gresele P, et al. Survey of lupus anticoagulant diagnosis by central evalua- tion of positive plasma samples. J Thromb Hae- most. 2007;5:925-930.
  33. Greaves M, Cohen H, MacHin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol. 2000;109:704-715.
  34. Wong RC, Adelstein S, Gillis D, Favaloro EJ. De- velopment of consensus guidelines for anticardio- lipin and lupus anticoagulant testing. Semin Thromb Hemost. 2005;31:39-48.
  35. Brandt JT, Triplett DA, Alving B, Scharrer I. Cri- teria for the diagnosis of lupus anticoagulants: an update: on behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995;74:1185- 1190.
  36. Tripodi A. Laboratory testing for lupus anticoagu- lants: a review of issues affecting results. Clin Chem. 2007;53:1629-1635.
  37. Gardiner C, MacKie IJ, Malia RG, et al. The im- portance of locally derived reference ranges and standardized calculation of dilute Russell's viper venom time results in screening for lupus antico- agulant. Br J Haematol. 2000;111:1230-1235.
  38. Rosner E, Pauzner R, Lusky A, Modan M, Many A. Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Hae- most. 1987;57:144-147.
  39. Rauch J, Tannenbaum M, Janoff AS. Distinguish- ing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospho- lipids. Thromb Haemost. 1989;62:892-896.
  40. Roussi J, Roisin JP, Goguel A. Lupus anticoagu- lants: first French interlaboratory Etalonorme sur- vey. Am J Clin Pathol. 1996;105:788-793.
  41. Brandt JT, Triplett DA, Rock WA, Bovill EG, Arkin CF. Effect of lupus anticoagulants on the activated partial thromboplastin time: results of the College of American Pathologists survey program. Arch Pathol Lab Med. 1991;115:109- 114.
  42. Jennings I, Greaves M, Mackie IJ, Kitchen S, Woods TA, Preston FE. Lupus anticoagulant testing: improvements in performance in a UK NEQAS proficiency testing exercise after dissemination of national guidelines on labora- tory methods. Br J Haematol. 2002;119:364- 369.
  43. Tripodi A, Mancuso ME, Chantarangkul V, et al. Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: con- siderations on the differentiation between the 2 circulating anticoagulants. Clin Chem. 2005;51: 1883-1885.
  44. Sletnes KE, Gravem K, Wisloff F. Preparation of plasma for the detection of lupus anticoagulants and antiphospholipid antibodies. Thromb Res. 1992;66:43-53.
  45. Moore GW, Smith MP, Savidge GF. The Ecarin time is an improved confirmatory test for the Tai- pan snake venom time in warfarinized patients with lupus anticoagulants. Blood Coagul Fibrino- lysis. 2003;14:307-312.
  46. Arnout J, Meijer P, Vermylen J. Lupus antico- agulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against hu- man beta2-glycoprotein I. Thromb Haemost. 1999;81:929-934.
  47. Jennings I, Mackie I, Arnout J, Preston FE. Lupus anticoagulant testing using plasma spiked with monoclonal antibodies: performance in the UK NEQAS proficiency testing programme. J Thromb Haemost. 2004;2:2178-2184.
  48. Simmelink MJ, Derksen RH, Arnout J, De Groot PG. A simple method to discriminate between beta2-glycoprotein I-and prothrombin-dependent lupus anticoagulants. J Thromb Haemost. 2003; 1:740-747.
  49. Pengo V, Biasiolo A, Pegoraro C, Iliceto S. A two- step coagulation test to identify antibeta-glyco- protein I lupus anticoagulants. J Thromb Hae- most. 2004;2:702-707.
  50. de Laat HB, Derksen RH, Urbanus RT, Roest M, de Groot PG. Beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with throm- bosis in the antiphospholipid syndrome. Blood. 2004;104:3598-3602.
  51. Harris EN, Pierangeli SS. Revisiting the anticar- diolipin test and its standardization. Lupus. 2002; 11:269-275.
  52. Harris EN, Gharavi AE, Patel SP, Hughes GR. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol. 1987;68:215-222.
  53. Wong RC. Consensus guidelines for anticardio- lipin antibody testing. Thromb Res. 2004;114: 559-571.
  54. Audrain MA, Colonna F, Morio F, Hamidou MA, Muller JY. Comparison of different kits in the de- tection of autoantibodies to cardiolipin and beta2glycoprotein 1. Rheumatology (Oxf). 2004; 43:181-185.
  55. Pierangeli SS, Harris EN. A protocol for determi- nation of anticardiolipin antibodies by ELISA. Nat Protoc. 2008;3:840-848.
  56. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syn- drome. Blood. 2003;102:2717-2723.
  57. Ichikawa K, Tsutsumi A, Atsumi T, et al. A chimeric antibody with the human gamma1 constant re- gion as a putative standard for assays to detect IgG beta2-glycoprotein I-dependent anticardio- lipin and anti-beta2-glycoprotein I antibodies. Ar- thritis Rheum. 1999;42:2461-2470.
  58. Reber G, de Moerloose P. Anti-beta2-glycoprotein I antibodies: when and how should they be mea- sured? Thromb Res. 2004;114:527-531.
  59. Favaloro EJ, Wong RC, Jovanovich S, Roberts- Thomson P. A review of beta2 -glycoprotein-l anti- body testing results from a peer-driven multilabo- ratory quality assurance program. Am J Clin Pathol. 2007;127:441-448.
  60. Reber G, Schousboe I, Tincani A, et al. Inter-labo- ratory variability of anti-beta2-glycoprotein I mea- surement: a collaborative study in the frame of the European Forum on Antiphospholipid Anti- bodies Standardization Group. Thromb Haemost. 2002;88:66-73.
  61. Kato H, Enjyoji K. Amino acid sequence and loca- tion of the disulfide bonds in bovine beta 2 glyco- protein I: the presence of five Sushi domains. Bio- chemistry. 1991;30:11687-11694.
  62. Giles IP, Isenberg DA, Latchman DS, Rahman A. How do antiphospholipid antibodies bind beta2- glycoprotein I? Arthritis Rheum. 2003;48:2111- 2121.
  63. Ambrozic A, Avicin T, Ichikawa K, et al. Anti- beta(2)-glycoprotein I antibodies in children with atopic dermatitis. Int Immunol. 2002;14:823-830.
  64. Zoghlami-Rintelen C, Vormittag R, Sailer T, et al. The presence of IgG antibodies against beta2- glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost. 2005;3:1160-1165.
  65. Sailer T, Vormittag R, Zoghlami C, et al. The clini- cal significance of anti-prothrombin antibodies for risk assessment of thromboembolism in patients with lupus anticoagulant. Thromb Res. 2007;120: 295-302.
  66. Horbach DA, van Oort E, Derksen RH, de Groot PG. The contribution of anti-prothrombin-antibod- ies to lupus anticoagulant activity: discrimination between functional and non-functional anti-pro- thrombin-antibodies. Thromb Haemost. 1998;79: 790-795.
  67. Vlachoyiannopoulos PG, Petrovas C, Tektonidou M, Krilis S, Moutsopoulos HM. Antibodies to beta 2-glycoprotein-I: urea resistance, binding speci- ficity, and association with thrombosis. J Clin Im- munol. 1998;18:380-391.
  68. Cucnik S, Kveder T, Krizaj I, Rozman B, Bozic B. High avidity anti-beta 2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Ann Rheum Dis. 2004;63:1478-1482.
  69. Cucnik S, Bozic B, Kveder T, Tomsic M, Rozman B. Avidity of anti-beta2-glycoprotein I and throm- bosis or pregnancy loss in patients with antiphos- pholipid syndrome. Ann N Y Acad Sci. 2005;1051: 141-147.
  70. de Laat B, Derksen RH, de Groot PG. High-avid- ity anti-beta glycoprotein I antibodies highly corre- late with thrombosis in contrast to low-avidity anti- beta glycoprotein I antibodies. J Thromb Haemost. 2006;4:1619-1621.
  71. Metzger J, von Landenberg P, Kehrel M, Buhl A, Lackner KJ, Luppa PB. Biosensor analysis of beta2-glycoprotein I-reactive autoantibodies: evi- dence for isotype-specific binding and differentia- tion of pathogenic from infection-induced antibod- ies. Clin Chem. 2007;53:1137-1143.
  72. Lee EY, Lee CK, Lee TH, et al. Does the anti- beta2-glycoprotein I antibody provide additional information in patients with thrombosis? Thromb Res. 2003;111:29-32.
  73. Detkov Gil-Aguado A, Lavilla P, Cuesta MV, Fontan G, Pascual-Salcedo D. Do antibodies to beta2-glycoprotein 1 contribute to the better char- acterization of the antiphospholipid syndrome? Lupus. 1999;8:430-438.
  74. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the di- agnosis of antiphospholipid syndrome. Thromb Haemost. 2005;93:1147-1152.
  75. Ruffatti A, Tonello M, Del Ross T, et al. Antibody profile and clinical course in primary antiphospho- lipid syndrome with pregnancy morbidity. Thromb Haemost. 2006;96:337-341.
  76. Ruffatti A, Tonello M, Cavazzana A, Bagatella P, Pengo V. Laboratory classification categories and pregnancy outcome in patients with primary an- tiphospholipid syndrome prescribed antithrom- botic therapy. Thromb Res. 2008 May 5 [Epub ahead of print].
  77. Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glyco- protein I and prothrombin, and risk of thrombosis. J Thromb Haemost. 2005;3:1231-1238.
  78. Tincani A, Morozzi G, Afeltra A, et al. Antipro- thrombin antibodies: a comparative analysis of homemade and commercial methods. A collabo- rative study by the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA). Clin Exp Rheumatol. 2007;25:268-274.
  79. Atsumi T, Amengual O, Yasuda S, Koike T. Anti- prothrombin antibodies: are they worth assaying? Thromb Research. 2004;114:533-538.
  80. Sanmarco M, Gayet S, Alessi MC, et al. Antiphos- phatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis: a multicenter study with the participation of the Eu- ropean Forum on antiphospholipid antibodies. Thromb Haemost. 2007;97:949-954.
  81. Gris JC, Quere I, Sanmarco M, et al. Antiphos- pholipid and antiprotein syndromes in non-throm- botic, non-autoimmune women with unexplained recurrent primary early foetal loss: the Nimes Ob- stetricians and Haematologists Study-NOHA. Thromb Haemost. 2000;84:228-236.
  82. Tebo AE, Jaskowski TD, Phansalkar AR, Litwin CM, Branch DW, Hill HR. Diagnostic performance of phospholipid-specific assays for the evaluation of antiphospholipid syndrome. Am J Clin Pathol. 2008;129:870-875.
  83. Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombo- sis related to antiphospholipid antibodies in sys- temic lupus erythematosus: a meta-analysis. Lu- pus. 1997;6:467-473.
  84. Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythem- atosus. J Rheumatol. 2002;29:2531-2536.
  85. Wahl DG, Guillemin F, de Maistre E, Perret- Guillaume C, Lecompte T, Thibaut G. Meta-analy- sis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underly- ing autoimmune disease or previous thrombosis. Lupus. 1998;7:15-22.
  86. de Groot PG, Lutters B, Derksen RH, Lisman T, Meijers JC, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost. 2005;3:1993- 1997.
  87. Runchey SS, Folsom AR, Tsai MY, Cushman M, McGovern PD. Anticardiolipin antibodies as a risk factor for venous thromboembolism in a popula- tion-based prospective study. Br J Haematol. 2002;119:1005-1010.
  88. Naess IA, Christiansen SC, Cannegieter SC, Rosendaal FR, Hammerstroem J. A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study). J Thromb Haemost. 2006;4: 44-49.
  89. Schulman S, Svenungsson E, Granqvist S. Anti- cardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy: Duration of Anticoagulation Study Group. Am J Med. 1998;104:332-338.
  90. Brey RL. Antiphospholipid antibodies in young adults with stroke. J Thromb Thrombolysis. 2005; 20:105-112.
  91. Levine SR, Brey RL, Tilley BC, et al. Antiphos- pholipid antibodies and subsequent thrombo-oc- clusive events in patients with ischemic stroke. JAMA. 2004;291:576-584.
  92. Danowski A, Kickler TS, Petri M. Anti-beta2-gly- coprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol. 2006;33:1775- 1779.
  93. Nash MJ, Camilleri RS, Kunka S, Mackie IJ, Machin SJ, Cohen H. The anticardiolipin assay is required for sensitive screening for antiphospho- lipid antibodies. J Thromb Haemost. 2004;2: 1077-1081.
  94. Crowther MA, Ginsberg JS, Julian J, et al. A com- parison of two intensities of warfarin for the pre- vention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133-1138.
  95. Offelli P, Zanchetta M, Pedon L, et al. Thrombo- philia in young patients with cryptogenic stroke and patent foramen ovale (PFO). Thromb Hae- most. 2007;98:906-907.
  96. Moroney JT, Bagiella E, Paik MC, Sacco RL, Desmond DW. Risk factors for early recurrence after ischemic stroke: the role of stroke syndrome and subtype. Stroke. 1998;29:2118-2124.
  97. Palareti G, Leali N, Coccheri S, et al. Bleeding com- plications of oral anticoagulant treatment: an incep- tion-cohort, prospective collaborative study (ISCOAT): Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996;348:423-428.
  98. Opatrny L, David M, Kahn SR, Shrier I, Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoim- mune disease: a metaanalysis. J Rheumatol. 2006;33:2214-2221.
  99. Sailer T, Zoghlami C, Kurz C, et al. Anti-beta2- glycoprotein I antibodies are associated with pregnancy loss in women with the lupus antico- agulant. Thromb Haemost. 2006;95:796-801.
  100. Girardi G, Berman J, Redecha P, et al. Comple- ment C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest. 2003;112:1644-1654.
  101. Girardi G, Redecha P, Salmon JE. Heparin pre- vents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004;10:1222-1226.
  102. Berman J, Girardi G, Salmon JE. TNF-alpha is a critical effector and a target for therapy in an- tiphospholipid antibody-induced pregnancy loss. J Immunol. 2005;174:485-490.
  103. Ikematsu W, Luan FL, La Rosa L, et al. Human anticardiolipin monoclonal autoantibodies cause placental necrosis and fetal loss in BALB/c mice. Arthritis Rheum. 1998;41:1026-1039.
  104. Robertson SA, Roberts CT, van Beijering E, et al. Effect of beta2-glycoprotein I null mutation on re- productive outcome and antiphospholipid anti- body-mediated pregnancy pathology in mice. Mol Hum Reprod. 2004;10:409-416.
  105. Carter AM. Animal models of human placentation: a review. Placenta. 2007;28[suppl A]:S41-S47.
  106. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxf). 2002;41:924-929.
  107. Fulham MJ, Gatenby P, Tuck RR. Focal cerebral ischemia and antiphospholipid antibodies: a case for cardiac embolism. Acta Neurol Scand. 1994; 90:417-423.
  108. Passam F, Krilis S. Laboratory tests for the an- tiphospholipid syndrome: current concepts. Pa- thology. 2004;36:129-138.